Clinical Trial Update: Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates Fluzoparib with or without Bevacizumab as neoadjuvant therapy for advanced ovarian cancer, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: RECRUITING